More Post from the Author
- H12025 global IPO activity shows resilience amid market volatility, says EY
- Kilsar Raises $3.7M to Revolutionize Maintenance & Maintenance Training with AI
- Digital Campers, Pet Parents, and a Tent Camping Revival: Newbook Report Reveals What's Next for RV & Camping in 2025
- Advantech stellt AMAX IoT-Steuerungsplattformen mit deterministischer Echtzeitleistung und Flexibilitt vor
- Resideo To Release Second Quarter 2025 Financial Results on August 5, 2025
Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System
Published on Mon 3 Feb 2025 2:31:05 UTC

Company Contact Information
Consumers:
866-770-3024
[emailprotected]
Press:
[emailprotected]
MORRISTOWN, N.J., Jan. 31, 2025 /PRNewswire/ -- Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches could be multi-stacked, adhered one on top of the other, in a single product pouch. This transdermal system is manufactured by Kindeva Drug Delivery L.P., Northridge, CA and is distributed by Alvogen, Inc. as a private label distributor.
More Post from the Author
- H12025 global IPO activity shows resilience amid market volatility, says EY
- Kilsar Raises $3.7M to Revolutionize Maintenance & Maintenance Training with AI
- Digital Campers, Pet Parents, and a Tent Camping Revival: Newbook Report Reveals What's Next for RV & Camping in 2025
- Advantech stellt AMAX IoT-Steuerungsplattformen mit deterministischer Echtzeitleistung und Flexibilitt vor
- Resideo To Release Second Quarter 2025 Financial Results on August 5, 2025